Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imugene

- PMLiVE

IO Biotech announces new data supporting its therapeutic cancer vaccine

The vaccine showed promise when used in combination with Merck & Co’s Keytruda

- PMLiVE

Moderna/Merck’s cancer vaccine shows promise in high-risk melanoma patients

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Merck and Moderna’s personalised cancer vaccine shows promise in high-risk melanoma patients

The vaccine in combination with Keytruda reduced the risk of recurrence or death by 44%

- PMLiVE

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal

The vaccine is currently being evaluated as a treatment for high-risk melanoma patients

- PMLiVE

Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial

HER-Vaxx plus chemotherapy resulted in ORR of 50% compared to 29% for chemotherapy alone

- PMLiVE

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

- PMLiVE

Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

Fails late-stage stomach cancer study

- PMLiVE

Keytruda adds stomach cancer to growing list of US approvals

FDA clears the drug as a third-line option after chemotherapy

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

- PMLiVE

Mixed news for Lilly on cancer hope ramucirumab

Fails in phase III for breast cancer but better results for stomach cancer

- PMLiVE

Merck’s oncology vaccine fails lung cancer trial

Stimuvax unable to demonstrated improvement in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links